50DE1FDE-B85E-4677-B0F8-08275DA41A6E
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 7.917214191852825
- age_years
- 33
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.731
- G2M_CHECKPOINT+0.685
- MYC_TARGETS_V2+0.674
- MYC_TARGETS_V1+0.655
- DNA_REPAIR+0.512
- MITOTIC_SPINDLE+0.502
- UNFOLDED_PROTEIN_RESPONSE+0.459
- MTORC1_SIGNALING+0.440
- WNT_BETA_CATENIN_SIGNALING+0.419
- CHOLESTEROL_HOMEOSTASIS+0.335
Top 10 suppressed
- KRAS_SIGNALING_DN-0.414
- MYOGENESIS-0.325
- BILE_ACID_METABOLISM-0.296
- PANCREAS_BETA_CELLS-0.196
- XENOBIOTIC_METABOLISM-0.175
- ESTROGEN_RESPONSE_LATE-0.121
- SPERMATOGENESIS-0.102
- COAGULATION-0.087
- APICAL_SURFACE-0.085
- KRAS_SIGNALING_UP-0.083
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 592CC5DC-4DB7-4961-AB2B-89C8FE4A83D3 | — | — | 0.960 |
| 2 | 98D004A9-E3F0-448E-BFE2-359F25DF356C | — | — | 0.946 |
| 3 | 9970B75F-7AC6-431B-BDBB-120D01582CBE | — | — | 0.945 |
| 4 | SRR934851 | — | — | 0.930 |
| 5 | C8E7072F-6FBB-4BF8-8917-0C0CBDAF7605 | — | — | 0.926 |
| 6 | SRR934964 | — | — | 0.924 |
| 7 | SRR934902 | — | — | 0.921 |
| 8 | C4C1F171-9B72-4527-9C03-39C2C00A5B6C | — | — | 0.914 |
| 9 | DAE9D154-5E0C-4961-9110-9E5653AAA787 | — | — | 0.914 |
| 10 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.731 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.685 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.674 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.655 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.512 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.502 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.459 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.440 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.419 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.335 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.321 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.298 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.275 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.257 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.255 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.247 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.242 | Remibrutinib | — uncovered |
| NOTCH_SIGNALING | 0.242 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.217 | Inavolisib | — uncovered |